SCHEMBL3480656

SCHEMBL3480656

[CH2]CCCN(CC=C)CC=C

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALDH1A1 P00352 2/20 0.31
HTR1A P08908 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
SLC6A2 P23975 1/20 0.31
HTR1D P28221 1/20 0.31
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
HTR1E P28566 1/20 0.31
SLC6A4 P31645 1/20 0.31
ADRA1A P35348 1/20 0.31
HRH1 P35367 1/20 0.31
ADRA1B P35368 1/20 0.31
DRD3 P35462 1/20 0.31
OPRK1 P41145 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL195772 0.92 KDM4E (0.31) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL213436 0.85 ALDH1A1 (0.35) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL2699253 0.85 ALDH1A1 (0.35) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6943640 0.82 KDM4E (0.33) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL192060 0.82 KDM4E (0.33) KDM4EMEN1KMT2ASMN1; SMN2HTR1A
SCHEMBL3060057 0.82 KDM4E (0.33) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6527091 0.82 OPRK1 (0.35) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3655351 0.82 KDM4E (0.33) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL11141982 0.80 OPRK1 (0.33) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL127488 0.78 TSHR (0.38) KDM4EMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2010530464-A 2010-09-09 JP claimed
EP-2160414-A2 POLYMERS FUNCTIONALIZED WITH HALOSILANES CONTAINING AN AMINO GROUP Bridgestone Corporation (JP) 2010-03-10 EP claimed
WO-2008156788-A2 POLYMERS FUNCTIONALIZED WITH HALOSILANES CONTAINING AN AMINO GROUP BRIDGESTONE CORPORATION (JP) 2008-12-24 WO claimed
US-20240059846-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES ALLARTA LIFE SCIENCE INC (CA) 2024-02-22 US disclosed
EP-4255965-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES Allarta Life Science Inc. (CA) 2023-10-11 EP disclosed
CN-116829621-A Reactive microparticles and use thereof for preparing functional hydrogel particles 奥立达生命科学公司 2023-09-29 CN disclosed
WO-2022120478-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES ALLARTA LIFE SCIENCE INC. (CA) 2022-06-16 WO disclosed
EP-2160414-A2 POLYMERS FUNCTIONALIZED WITH HALOSILANES CONTAINING AN AMINO GROUP Bridgestone Corporation (JP) 2010-03-10 EP disclosed
WO-2008156788-A2 POLYMERS FUNCTIONALIZED WITH HALOSILANES CONTAINING AN AMINO GROUP BRIDGESTONE CORPORATION (JP) 2008-12-24 WO disclosed
US-7238467-B2 Silver halide emulsion, method of preparing the same and silver halide photosensitive material using the same FUJIFILM CORPORATION (JP) 2007-07-03 US disclosed
US-6903117-B2 Indole derivatives for the treatment of osteoporosis NIKEM RESEARCH S.R.L. (IT) 2005-06-07 US disclosed
EP-0912560-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1999-05-06 EP disclosed
WO-1998001423-A1 5-INDOLYL-2,4-PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed
WO-1998001436-A1 HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed
WO-1998001445-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed
WO-1998001443-A1 INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1998-01-15 WO disclosed
EP-0802902-A1 INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS Smithkline Beecham S.p.A. (IT) 1997-10-29 EP disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
WO-1996021644-A1 INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF OSTEOPOROSIS SMITHKLINE BEECHAM S.P.A. (IT) 1996-07-18 WO disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059846-A1 REACTIVE MICROPARTICLES AND THEIR USE TO PREPARE FUNCTIONAL HYDROGEL PARTICLES LTA, VCL, HBB KDM4E 2509/4885MEN1 1266/4885KMT2A 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.